5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 9.64▼ | 10.22▼ | 10.22▼ | 9.97▲ | 9.97▲ |
MA10 | 10.36▼ | 11.22▼ | 11.22▼ | 9.87▲ | 11.17▼ |
MA20 | 11.25▼ | 11.90▼ | 11.90▼ | 10.11▼ | 11.69▼ |
MA50 | 11.79▼ | 11.76▼ | 11.59▼ | 11.33▼ | 13.88▼ |
MA100 | 11.85▼ | 13.04▼ | 13.50▼ | 11.77▼ | 15.16▼ |
MA200 | 14.86▼ | 15.26▼ | 15.30▼ | 13.15▼ | 20.67▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.259▼ | -0.348▼ | -0.344▼ | 0.100▲ | -0.147▼ |
RSI | 32.232▼ | 32.774▼ | 33.427▼ | 44.621▼ | 40.328▼ |
STOCH | 4.083▼ | 9.316▼ | 9.316▼ | 64.570 | 18.829▼ |
WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -28.931 | -77.079▼ |
CCI | -83.297 | -141.500▼ | -141.500▼ | 92.038 | -108.548▼ |
Thursday, September 18, 2025 09:14 AM
Roche Holding AG acquires 89bio Inc. for $3.5B, adding promising MASH and hypertriglyceridemia treatments. Click for more on RHHBY and ETNB stocks.
|
Thursday, September 18, 2025 12:36 AM
Shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradeable CVR to receive certain milestone payments of up to an aggregate of $6.00 per share in cash, representing a ...
|
Wednesday, September 17, 2025 10:11 PM
Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesityAcquisition supports Roche’s strategy as it enhances the company’s portfolio in ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
17/09/25 | 10.00 | 10.10 | 10.00 | 10.10 | 1,800 |
16/09/25 | 9.01 | 10.24 | 9.01 | 10.24 | 4,677 |
15/09/25 | 9.80 | 9.80 | 9.80 | 9.80 | 0 |
12/09/25 | 9.95 | 9.95 | 9.80 | 9.80 | 700 |
11/09/25 | 9.93 | 9.93 | 9.93 | 9.93 | 300 |
10/09/25 | 9.51 | 10.11 | 9.50 | 10.11 | 4,800 |
09/09/25 | 9.50 | 10.56 | 9.50 | 10.56 | 3,000 |
08/09/25 | 9.20 | 9.43 | 9.20 | 9.43 | 10,900 |
05/09/25 | 9.21 | 9.56 | 8.97 | 9.20 | 8,500 |
04/09/25 | 9.52 | 9.52 | 9.52 | 9.52 | 300 |
|
|
||||
|
|
||||
|
|